>
Switch to:

Orgenesis Net Current Asset Value

: $0.01 (As of Mar. 2022)
View and export this data going back to 2010. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Orgenesis's net current asset value per share for the quarter that ended in Mar. 2022 was $0.01.

The historical rank and industry rank for Orgenesis's Net Current Asset Value or its related term are showing as below:

ORGS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.37   Med: 10.19   Max: 16
Current: 13.28

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Orgenesis was 16.00. The lowest was 4.37. And the median was 10.19.

ORGS's Price-to-Net-Current-Asset-Value is ranked worse than
87.03% of 1218 companies
in the Biotechnology industry
Industry Median: 3.14 vs ORGS: 13.28

Orgenesis Net Current Asset Value Historical Data

The historical data trend for Orgenesis's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Net Current Asset Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.87 -1.12 -0.54 1.03 0.18

Orgenesis Quarterly Data
May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Net Current Asset Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.96 0.58 0.18 0.01

Competitive Comparison

For the Biotechnology subindustry, Orgenesis's Net Current Asset Value, along with its competitors' market caps and Net Current Asset Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Orgenesis Net Current Asset Value Distribution

For the Biotechnology industry and Healthcare sector, Orgenesis's Net Current Asset Value distribution charts can be found below:

* The bar in red indicates where Orgenesis's Net Current Asset Value falls into.



Orgenesis Net Current Asset Value Calculation

Orgenesis's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net Current Asset Value Per Share(A: Dec. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(25.758-21.21-0.143-0)/24.2808
=0.18

Orgenesis's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2022 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(24.01-23.681-0.155-0)/24.601
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orgenesis  (NAS:ORGS) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener. GuruFocus also publishes a monthly Net-Net newsletter.


Orgenesis Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Orgenesis's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)